"Neostigmine" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A cholinesterase inhibitor used in the treatment of myasthenia gravis and to reverse the effects of muscle relaxants such as gallamine and tubocurarine. Neostigmine, unlike PHYSOSTIGMINE, does not cross the blood-brain barrier.
| Descriptor ID |
D009388
|
| MeSH Number(s) |
D02.092.877.674.666 D02.675.276.602
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Neostigmine".
Below are MeSH descriptors whose meaning is more specific than "Neostigmine".
This graph shows the total number of publications written about "Neostigmine" by people in this website by year, and whether "Neostigmine" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2004 | 1 | 0 | 1 |
| 2021 | 0 | 1 | 1 |
| 2024 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Neostigmine" by people in Profiles.
-
Tsouknidas I, Perez S, Kunkel E, Tiko-Okoye C, Buckley ME, Gefen JY. Use of sugammadex in prevention of post-operative urinary retention in minimally invasive hernia surgery. Hernia. 2024 Aug; 28(4):1325-1330.
-
Mraovic B, Timko NJ, Choma TJ. Comparison of recovery after sugammadex or neostigmine reversal of rocuronium in geriatric patients undergoing spine surgery: a randomized controlled trial. Croat Med J. 2021 Dec 31; 62(6):606-613.
-
Amato CS, Wang RY, Wright RO, Linakis JG. Evaluation of promotility agents to limit the gut bioavailability of extended-release acetaminophen. J Toxicol Clin Toxicol. 2004; 42(1):73-7.